News

AbbVie, Voyager Team Up to Develop Antibodies for Parkinson’s, Other Diseases

AbbVie and Voyager Therapeutics have extended their collaboration to co-develop and commercialize antibodies that target the toxic forms of alpha-synuclein to treat Parkinson’s disease and other synucleinopathies. The collaboration will combine AbbVie’s expertise in monoclonal antibodies with Voyager’s gene therapy platform to deliver antibodies across the blood-brain barrier…

Having a Heart, Lung, Kidney, or Bone-Marrow Transplant May Lower Risk of Developing Parkinson’s

People who have had kidney, heart, lung, or bone-marrow transplants are less likely to develop Parkinson’s disease than the general population, research suggests. The study, “Transplant and risk of Parkinson disease” was published recently in Parkinsonism & Related Disorders.  Chronic neuroinflammation is a hallmark of Parkinson’s disease with…

Stem Cell Transplants Could Significantly Improve Parkinson’s Treatment, Study Suggests

Cell replacement therapies in which dopamine-producing stem cells are transplanted into Parkinson’s disease patients could improve motor symptoms, reducing or eliminating the need for dopaminergic medicines, a study suggests. The study, “Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies,” was published in the Journal of …